Company intelligence / Profile preview

StemCells, Inc.

Newark, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

The company showed preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells in a Phase I clinical trial for Pelizaeus-Merzbacher disease. They were also conducting Phase I/II clinical trials in chronic spinal cord injury and dry age-related macular degeneration, with positive interim data reported for the first three patients in the spinal cord injury trial.

Therapeutic areas: OphthalmologyNeurology
Modalities: Cell-based therapeutics (human neural stem cells)
Industry: Biotech

Drug pipeline

3 assets

human central nervous system stem cells

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on StemCells, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StemCells, Inc..

Explore the full profile